These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31605777)

  • 21. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.
    Rampling R; Cruickshank G; Papanastassiou V; Nicoll J; Hadley D; Brennan D; Petty R; MacLean A; Harland J; McKie E; Mabbs R; Brown M
    Gene Ther; 2000 May; 7(10):859-66. PubMed ID: 10845724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus as an oncomodulatory agent in the progression of glioma.
    Joseph GP; McDermott R; Baryshnikova MA; Cobbs CS; Ulasov IV
    Cancer Lett; 2017 Jan; 384():79-85. PubMed ID: 27777041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating recurrent glioblastoma: an update.
    Kamiya-Matsuoka C; Gilbert MR
    CNS Oncol; 2015; 4(2):91-104. PubMed ID: 25768333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Advance of molecular subtyping and precise treatment for gliomas].
    Hua W; Mao Y
    Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):63-66. PubMed ID: 28056258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment considerations for MGMT-unmethylated glioblastoma.
    Taylor JW; Schiff D
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Occurrence and molecular pathology of high grade gliomas].
    Murnyák B; Csonka T; Hegyi K; Méhes G; Klekner A; Hortobágyi T
    Ideggyogy Sz; 2013 Sep; 66(9-10):312-21. PubMed ID: 24358686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
    Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
    Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glioblastoma multiforme: Pathogenesis and treatment.
    Alifieris C; Trafalis DT
    Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Glioblastoma, Present and Future.
    Oberheim Bush NA; Hervey-Jumper SL; Berger MS
    World Neurosurg; 2019 Nov; 131():328-338. PubMed ID: 31658576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omics sciences and precision medicine in glioblastoma.
    Micheletti C; Bonetti G; Madeo G; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Manganotti P; Caruso P; Bernini A; Fulcheri E; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
    Clin Ter; 2023; 174(Suppl 2(6)):77-84. PubMed ID: 37994751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten-year review of survival and management of malignant glioma in Hong Kong.
    Chan DT; Hsieh SY; Lau CK; Kam MK; Loong HH; Tsang WK; Poon DM; Poon WS
    Hong Kong Med J; 2017 Apr; 23(2):134-9. PubMed ID: 27909268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
    Lau D; Magill ST; Aghi MK
    Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
    Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
    Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-grade gliomas in children.
    Cage TA; Mueller S; Haas-Kogan D; Gupta N
    Neurosurg Clin N Am; 2012 Jul; 23(3):515-23. PubMed ID: 22748663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miRNA Multiplayers in glioma. From bench to bedside.
    Rolle K
    Acta Biochim Pol; 2015; 62(3):353-65. PubMed ID: 26307768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glioma models.
    Dai C; Holland EC
    Biochim Biophys Acta; 2001 Aug; 1551(1):M19-27. PubMed ID: 11553418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telomerase inhibition in malignant gliomas: a systematic review.
    D'Alessandris QG; Battistelli M; Pennisi G; Offi M; Martini M; Cenci T; Falchetti ML; Lauretti L; Olivi A; Pallini R; Montano N
    Expert Rev Mol Med; 2023 Mar; 25():e10. PubMed ID: 36919343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.